These limitations highlight the need for future studies with larger clinical cohorts, tissue-specific functional experiments, and animal models to fully validate and expand the role of the CXCL1–ERS–TXNDC5 axis in atrial remodeling and AF pathogenesis. This evidence concerns the gene TXNDC5 and atrial fibrillation.